Update on clinical development program
16/04/2026 – AB Science provides an update on its clinical development program
Read more
therapies in diseases
with high medical need
Latest news
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
24/02/2026 – AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS)
FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®
09/02/2026 – AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
29/01/2026 – AB Science announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent relating to methods of treating metastatic castrate resistant prostate cancer (mCRPC)
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
21/01/2026 – AB Science today announced that the Japanese Patent Office has formally granted a patent for methods of treating progressive multiple sclerosis (MS) with its lead compound masitinib
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
07/01/2026 – AB Science today provides an update on the Phase 1 study of the molecule AB8939 and the fourth consecutive response with the combination of AB8939 + venetoclax in patients with acute myeloid leukemia